Bioxyne Limited (AU:BXN)
ASX:BXN
Want to see AU:BXN full AI Analyst Report?
BXN Stock Chart & Stats
AU$0.04
<AU$0.01(4.17%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.09
Previous CloseN/A
Volume631.90K
Average Volume (3M)4.35M
Market Cap
AU$168.83M
Enterprise ValueAU$154.23M
Total Cash (Recent Filing)AU$7.60M
Total Debt (Recent Filing)AU$7.43M
Price to Earnings (P/E)3.2
Beta1.38
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,281,433,300
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And ProfitabilitySustained 77% revenue growth coupled with healthy net (16.1%) and EBIT (16.8%) margins indicates expanding product adoption and improving unit economics. Over 2-6 months this supports reinvestment, capacity expansion, and a stronger competitive position versus slower peers.
Material Improvement In Cash GenerationA dramatic increase in free cash flow and solid cash conversion ratios signal stronger internal funding for operations and capex. Durable cash generation reduces reliance on external finance and supports sustained product development, regulatory costs, and commercial rollouts.
Conservative Leverage With High ROEVery low leverage limits interest burden and financial fragility while a high ROE shows effective capital use. This combination provides balance-sheet flexibility to pursue licensing, manufacturing scale-up, or absorb regulatory development costs without compromising long-term solvency.
Bears Say
Modest Gross MarginA comparatively modest gross margin (34.3%) constrains the company’s ability to expand EBITDA proportionally as revenue grows. Over months this makes profitability sensitive to input costs, scale inefficiencies, or pricing pressure, requiring manufacturing or procurement improvements to sustain margins.
Regulatory Dependence For RevenueRevenue and market access depend on regulatory approvals and product listings. These structural dependencies can delay launches, constrain market expansion or alter prescribing dynamics, creating multi-month variability in sales trajectories and requiring sustained compliance resources.
Limited Operational Scale / Small HeadcountA very small workforce implies limited internal capacity across cultivation, manufacturing, regulatory affairs and commercial functions. Scaling distribution, supporting clinics/pharmacies, and meeting complex GMP requirements may need substantial hiring or partners, raising execution risk over the medium term.
Bioxyne Limited News
BXN FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.09 in the past 12 months.
What is Bioxyne Limited’s market cap?
Bioxyne Limited’s market cap is AU$168.83M.
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 97 days.
How were Bioxyne Limited’s earnings last quarter?
Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 2,281,433,300 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxyne Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BXN Sentiment 94%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$90.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
56.29%
Trailing 12-Months
Asset Growth
131.94%
Trailing 12-Months
Company Description
Bioxyne Limited
Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Technical Analysis
Wellnex Life Ltd
―
EVE Health Group Limited
―
Holista Colltech Limited
―
Clover Corporation Limited
―
Maggie Beer Holdings Ltd.
―
Options Prices
Currently, No data available
---